Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital

Real-world data from a retrospective cohort study showed that among patients with bone-metastatic breast cancer, non-small cell lung cancer, and prostate cancer, 47%, 87%, and 88%, respectively, did not receive a bone-targeting agent (BTA). Among those patients who did receive a BTA, median time from bone metastases diagnosis to BTA initiation was 65 (27-167), 60 (28-162), and 610 (295-980) days, respectively.